Center for Advanced Preclinical Research: Glioblastoma Multiforme
Both conditional GEM and GEM-derived orthotopic models for glioblastoma multiforme (GBM) are available.
- Harboring alterations in RTK/RAS/PI3K/PTEN and Rb, the GBM model develops spontaneous p53 aberrations and retains the key characteristics of the human disease (Song et al., PNAS 2013).
- These engineered mutations result in major alterations of three signaling pathways critical to human GBM (Ceccarelli et al. Cell 2016).
The GEM-derived orthotopic mouse brain tumor model recapitulates major signaling pathways altered in human GBM along with key features of human GBM histopathology, and is a platform for evaluating pathway-targeted therapies.
Orthotopic tumor-bearing mouse cohorts are created by intracranial injection of GEM-GBM derived primary cells in syngeneic immunocompetent mice.
TRP orthotopic GBM model tumor growth is monitored by MRI at baseline and during drug treatment. The model has a short latency and is optimized to be tractable and reliable for conducting preclinical studies.